Tekla Capital Management’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | $118M | Sell |
1,533,884
-26,000
| -2% | -$2.07M | 4.63% | 3 |
|
|
2023
Q1 | $129M | Buy |
1,559,884
+49,444
| +3% | +$4.1M | 4.93% | 2 |
|
|
2022
Q4 | $130M | Sell |
1,510,440
-111,725
| -7% | -$8.85M | 4.9% | 3 |
|
|
2022
Q3 | $100M | Sell |
1,622,165
-28,600
| -2% | -$1.8M | 4.1% | 4 |
|
|
2022
Q2 | $102M | Sell |
1,650,765
-35,800
| -2% | -$2.22M | 4.01% | 3 |
|
|
2022
Q1 | $100M | Hold |
1,686,565
| – | – | 3.52% | 5 |
|
|
2021
Q4 | $122M | Sell |
1,686,565
-21,500
| -1% | -$1.48M | 3.94% | 4 |
|
|
2021
Q3 | $119M | Buy |
1,708,065
+73,280
| +4% | +$5.15M | 3.84% | 4 |
|
|
2021
Q2 | $113M | Sell |
1,634,785
-181,121
| -10% | -$12.1M | 3.66% | 3 |
|
|
2021
Q1 | $117M | Buy |
1,815,906
+410,535
| +29% | +$26.5M | 4.04% | 1 |
|
|
2020
Q4 | $81.9M | Sell |
1,405,371
-238,312
| -14% | -$14.4M | 2.88% | 5 |
|
|
2020
Q3 | $104M | Buy |
1,643,683
+62,657
| +4% | +$4.35M | 3.89% | 4 |
|
|
2020
Q2 | $122M | Sell |
1,581,026
-307,279
| -16% | -$23.5M | 4.63% | 3 |
|
|
2020
Q1 | $141M | Sell |
1,888,305
-2,271
| -0.1% | -$157K | 6.38% | 1 |
|
|
2019
Q4 | $123M | Buy |
1,890,576
+56,594
| +3% | +$3.69M | 4.65% | 3 |
|
|
2019
Q3 | $116M | Sell |
1,833,982
-2,130
| -0.1% | -$139K | 5.07% | 3 |
|
|
2019
Q2 | $124M | Buy |
1,836,112
+86,724
| +5% | +$5.71M | 5.06% | 3 |
|
|
2019
Q1 | $114M | Sell |
1,749,388
-140,458
| -7% | -$9.34M | 4.62% | 4 |
|
|
2018
Q4 | $118M | Sell |
1,889,846
-52,471
| -3% | -$3.67M | 5.06% | 4 |
|
|
2018
Q3 | $150M | Sell |
1,942,317
-121,382
| -6% | -$9.17M | 5.44% | 1 |
|
|
2018
Q2 | $146M | Hold |
2,063,699
| – | – | 5.55% | 1 |
|
|
2018
Q1 | $156M | Sell |
2,063,699
-456,582
| -18% | -$36.3M | 6.05% | 1 |
|
|
2017
Q4 | $181M | Sell |
2,520,281
-280,850
| -10% | -$21.3M | 6.96% | 1 |
|
|
2017
Q3 | $227M | Buy |
2,801,131
+271,000
| +11% | +$20.7M | 8.11% | 1 |
|
|
2017
Q2 | $179M | Hold |
2,530,131
| – | – | 6.63% | 2 |
|
|
2017
Q1 | $172M | Hold |
2,530,131
| – | – | 6.66% | 1 |
|
|
2016
Q4 | $181M | Sell |
2,530,131
-130,000
| -5% | -$9.66M | 7.72% | 1 |
|
|
2016
Q3 | $210M | Buy |
2,660,131
+148,400
| +6% | +$12.1M | 8.09% | 1 |
|
|
2016
Q2 | $210M | Buy |
2,511,731
+180,500
| +8% | +$16M | 8.55% | 1 |
|
|
2016
Q1 | $214M | Hold |
2,331,231
| – | – | 9.11% | 1 |
|
|
2015
Q4 | $236M | Buy |
2,331,231
+109,800
| +5% | +$11.4M | 8.55% | 1 |
|
|
2015
Q3 | $218M | Buy |
2,221,431
+141,700
| +7% | +$15.7M | 7.84% | 1 |
|
|
2015
Q2 | $243M | Sell |
2,079,731
-200,000
| -9% | -$21.9M | 8.81% | 1 |
|
|
2015
Q1 | $224M | Buy |
2,279,731
+199,000
| +10% | +$20.2M | 8.86% | 2 |
|
|
2014
Q4 | $196M | Sell |
2,080,731
-409,800
| -16% | -$42.4M | 9.18% | 2 |
|
|
2014
Q3 | $265M | Buy |
2,490,531
+985,819
| +66% | +$96.5M | 12.43% | 1 |
|
|
2014
Q2 | $125M | Hold |
1,504,712
| – | – | 11.45% | 1 |
|
|
2014
Q1 | $107M | Hold |
1,504,712
| – | – | 10.66% | 1 |
|
|
2013
Q4 | $113M | Hold |
1,504,712
| – | – | 11.87% | 1 |
|
|
2013
Q3 | $94.6M | Hold |
1,504,712
| – | – | 10.52% | 1 |
|
|
2013
Q2 | $77.1M | Buy |
+1,504,712
| New | +$78.4M | 10.48% | 1 |
|
Other funds holding GILD
Tekla Capital Management's GILD Position: Q2 2023 in Review
Tekla Capital Management reduced its Gilead Sciences (GILD) stake by 1.7% in Q2 2023, selling an estimated $2.07M and leaving 1,533,884 shares worth $118M. The position accounts for 4.63% of the portfolio, ranked #3.
Tekla Capital Management first reported a position in GILD in Q2 2013 and has held it in 41 quarters since. The position peaked at $265M in Q3 2014. 1,702 funds tracked by Wall St. Rank hold GILD as of Q2 2023.
- Tekla Capital Management held 1,533,884 shares of Gilead Sciences worth $118M as of Q2 2023.
- Tekla Capital Management sold 26,000 Gilead Sciences shares in Q2 2023, an estimated $2.07M.
- Gilead Sciences made up 4.63% of Tekla Capital Management's portfolio in Q2 2023, its #3 holding.
- Tekla Capital Management first reported a position in Gilead Sciences in Q2 2013 and has held it in 41 quarters since.
- Tekla Capital Management's Gilead Sciences position peaked at $265M in Q3 2014.
- 1,702 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2023.
Based on Tekla Capital Management's 13F filing for Q2 2023, filed 10 Aug 2023.